• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

137.78 -5.59 (-3.90%)
Official Closing Price Updated: 7:00 PM EST, Nov 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,704,756
Open 141.09
Bid (Size) 137.30 (100)
Ask (Size) 137.90 (100)
Prev. Close 143.37
Today's Range 136.79 - 142.34
52wk Range 92.11 - 156.92
Shares Outstanding 2,531,374,696
Dividend Yield 2.47%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dow Jones Top Movers: Decliners Lead Nov. 18, 2026 Session ↗
November 18, 2026
Via Chartmill
Topics Stocks
Dow Jones Gainers and Losers: Top Movers in Nov. 18, 2026 US Session ↗
November 18, 2026
Via Chartmill
Topics Stocks

Performance

52-Week Range 12.2% below 52-week high
137.78
92.1152W Low 156.9252W High
1 Week 7.7% below 1-week high
136.791W Low 149.311W High

Merck & Co (MRK) traded between $92.11 and $156.92 over the past 52 weeks and last traded at $137.78, 12.2% below its 52-week high. Over the past week it ranged between $136.79 and $149.31.

Past 12 Months
-6.2%
-4.1%
-9.5%
+21.9%
+29.4%
+42.9%
1W -$9.17
1M -$5.85
3M -$14.42
6M +$24.78
YTD +$31.33
1Y +$41.35

MRK was +42.9% over the past year, +21.9% over six months, +29.4% year to date, -6.2% in the last week.

12 Months vs Market
MRK
+42.9%
DIA
+8.8%
SPY
+10.6%
QQQ
+10.6%
IWM
+15.7%

Over the past 12 months MRK returned +42.9% versus DIA (Dow) +8.8%, SPY (S&P 500) +10.6%, QQQ (Nasdaq 100) +10.6% and IWM (Russell 2000) +15.7%.

Volume & Liquidity 0.95× 3-mo avg
Today 9,704,756 3-mo avg 10.2M
1W
7.6M
1M
9.5M
3M
10.2M
6M
10.3M
YTD
10.5M
1Y
11.1M

MRK most recently traded 9,704,756 shares against a 3-month average daily volume of 10.2M.

More News

Read More
News headline image
Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
November 18, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
November 17, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces First-Quarter 2027 Dividend
November 17, 2026
From Merck & Co., Inc.
Via Business Wire
Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declines ↗
November 03, 2026
Via Chartmill
Topics Stocks
Dow Jones Biggest Decliners in Today's US Session ↗
November 03, 2026
Via Chartmill
Topics Stocks
News headline image
Is Merck's Stock Still a Good Buy at $150? ↗
November 16, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
November 13, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
November 13, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Pharmaceutical Stocks That Offer Safety and Growth ↗
November 12, 2026
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Merck to Participate in the Jefferies Global Healthcare Conference in London
November 12, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom ↗
November 11, 2026
Via MarketBeat
Topics Artificial Intelligence Bankruptcy
News headline image
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
November 09, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Moderna Just Gave Investors Yet Another Thing to Cheer About ↗
November 06, 2026
Via The Motley Fool
News headline image
2 Growth Stocks to Buy in November Without Any Hesitation ↗
November 05, 2026
Via The Motley Fool
News headline image
History Says This ETF Is a Fantastic Buy-and-Hold Investment -- and It Could Turn $100 per Month Into $359,492 ↗
November 04, 2026
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success ↗
November 03, 2026
Via The Motley Fool
News headline image
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively ↗
November 03, 2026
Via The Motley Fool
Topics Economy
News headline image
Tempus AI Surges on Earnings Beat, But Can the Rally Last? ↗
November 03, 2026
Via MarketBeat
Topics Artificial Intelligence Earnings Initial Public Offering
News headline image
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
November 03, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗
November 02, 2026
Via The Motley Fool
News headline image
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
November 02, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Why Merck Stock Flew Higher on Friday ↗
October 30, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
October 30, 2026
Via StockStory

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 137.78
When was Merck & Co last traded?
The last trade of Merck & Co was at 11/18/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 348.77B
How many shares of Merck & Co are outstanding?
Merck & Co has 349B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap